Introduction

The aim of this invention is the use of myelin nanovesicles (MyVes) in multiple sclerosis (MS) or in Central Nervous System (CNS) diseases. In particular, MyVes could be relevant for myelin repair and/or drug delivery system to the CNS and/or in the development of immunotolerance.

Technical features

A protocol for the MyVes production has been developed. MyVes have been characterized by chemical-physical approaches, and different parameters have been identified: size (˂100 nm), morphology (spheroidal), zeta potential (-37mV), stability ( > three months), and the presence of a phospholipid bilayer and proteins (20%).
MyVes vesicles have been partially characterized by the means of biological tests, and they are cytocompatible in neuronal cells and are able to interact with them. Finally, MyVes do not show a cytotoxic or activating effect on microglial cells.
Thanks to their nature and chemical-physical and biological characteristics, we foresee that the Myves can counteract the demyelinating pathologies of the CNS, and we foresee a direct action on the CNS through the intranasal route (nasal spray) less invasive or intravenously, across the blood-brain barrier.

Possible Applications

• reduced production costs;
• possible non-invasive administration;
• minimal adverse effects due to their biological nature;
• replenish the damaged myelin layer by intervening on the damage (disability);
• make the immune system tolerant to the presence of myelin.

Advantages

• Innovative tool for therapies against Multiple Sclerosisi or other demyelinating disease;
• Myves can be carrier for drugs to the central nervous system.